Aperio Group’s Astrana Health ASTH Stock Holding History

Aperio Group’s Portfolio ASTH Stock Details ASTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-255	Closed	-$4K	–	2784
2019 Q2	$4K	Buy	+255	New	+$4.63K	﹤0.01%	2878

Other funds holding ASTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aperio Group's ASTH Position: Q3 2019 in Review

Aperio Group sold out of Astrana Health (ASTH) in Q3 2019, closing a stake of 255 shares — an estimated $4K sold.

Aperio Group first reported a position in ASTH in Q2 2019 and held it in 1 quarter. The position peaked at $4K in Q2 2019. 46 funds tracked by Wall St. Rank hold ASTH as of Q3 2019.

Aperio Group reported no remaining Astrana Health position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 255 Astrana Health shares in Q3 2019, an estimated $4K.
Aperio Group first reported a position in Astrana Health in Q2 2019 and held it in 1 quarter.
Aperio Group's Astrana Health position peaked at $4K in Q2 2019.
46 funds tracked by Wall St. Rank held Astrana Health as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.